James Huang - 06 Sep 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 06 Sep 2022
Net transaction value: +$229,662
SEC form: 4
Accepted by SEC: 08 Sep 2022, 18:51:39 UTC
Prior SEC filing: 02 Sep 2022
Next SEC filing: 23 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ James Huang

Key filing fact

James Huang filed Form 4 for CASI Pharmaceuticals, Inc. on 08 Sep 2022.

Key facts

This page summarizes James Huang's Form 4 filing for CASI Pharmaceuticals, Inc..
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Sep 2022, 18:51.

Change

Previous filing in this sequence was filed on 02 Sep 2022.
Current net transaction value: +$229,662.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CASI transaction

Common Stock

Purchase

Transaction value: $74,601
Shares: +19,162
Change %: +6.1%
Price: $3.89^*
Shares after: 335,106
Date: 06 Sep 2022
Ownership: See Footnote
Footnotes: F1, F2

CASI transaction

Common Stock

Purchase

Transaction value: $12,433
Shares: +3,111
Change %: +0.93%
Price: $4.00^*
Shares after: 338,217
Date: 07 Sep 2022
Ownership: See Footnote
Footnotes: F2, F3

CASI transaction

Common Stock

Purchase

Transaction value: $142,627
Shares: +33,300
Change %: +9.8%
Price: $4.28^*
Shares after: 371,517
Date: 08 Sep 2022
Ownership: See Footnote
Footnotes: F2, F4

CASI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 191
Date: 06 Sep 2022
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $4.00. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F2

Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.

Footnote F3

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.9401 to $4.00. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.115 to $4.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.